期刊文献+

三氧化二砷和肼苯哒嗪体外诱导雌激素受体α表达强弱的比较 被引量:1

The Comparison of the Expression Effect of ER-α Induced by Arsenic Trioxide and Hydrazine
下载PDF
导出
摘要 目的本文拟比较三氧化二砷和肼苯哒嗪两种去甲基化药物在最佳有效浓度时,诱导MDA-MB-231细胞株雌激素受体重新表达作用的差异。方法以雌激素受体高甲基化失活的人乳腺细胞系MDA-MB-231细胞系为研究对象,经2.0μmol/LAs2O3和10μmol/L肼苯哒嗪处理后,采用免疫组织化学技术检测ER-α受体的表达。结果经2.0μmol/L As2O3与10μmol/L肼苯哒嗪处理的MDA-MB-231细胞ER-α受体的表达差异无统计学意义(P>0.05)。结论两种去甲基化药物在各自最佳去甲基化作用浓度时,对于高甲基化失活的雌激素受体ER-α基因去甲基化作用差异无统计学意义。 Objective This present study was designed to compare the effect of re-expression of the silenced estrogen receptor (ER-α) gene in human breast cell line MDA-MB-231 by arsenic trioxide (As2O3) and hydrazine. Methods The MDA-MB-231 cell line in which the estrogen receptor gene was silenced due to hypermethylation was treated with 2.0 μmol/L As2 03 and 10 μmol/L hydrazine,the expression levels of ER-α genes were determined with immunohistochemistry technique. Results The detectable expression effect of ER-α protein had not significant difference by arsenic trioxide and hydrazine (P 〉 0.05). Conclusions At their optimal concentration,the effect of re-expression of the silenced estrogen receptor gene was not different.
出处 《肿瘤基础与临床》 2007年第3期208-209,共2页 journal of basic and clinical oncology
关键词 甲基化 雌激素受体 三氧化二砷 人乳腺癌MDA-MB-231细胞系 肼苯哒嗪 DNA methylation estrogen receptor arsenic trioxide human breast cell line MDA-MB-231 hydrazine
  • 相关文献

参考文献7

二级参考文献28

  • 1唐建林,高东宸.用改良LSAB法检测乳腺癌雌激素受体和孕激素受体[J].中华病理学杂志,1994,23(2):120-121. 被引量:6
  • 2左文述 徐忠法 等.现代肿腺肿瘤学(第1版)[M].济南:山东科学技术出版社,1996.442.
  • 3杨骅 郁琳琳.三氧化二砷诱导乳癌细胞的凋亡[J].中国肿瘤生物治疗杂志,1997,(4):245-245.
  • 4左文述,现代乳腺肿瘤学,1996年,442页
  • 5卢圣栋,现代分子生物学实验技术,1993年,479页
  • 6Tanner M, Gancberg D, Di L A, et al. Chromogenic in situ hybridization: a practical alternative for flouresence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer sample[J]. Am J Pathol, 2000, 157(5): 1467-1472.
  • 7Meijers H H, Brekelmans C T, Menke P M, et al. Use of genetic test and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation[J]. J Clin Oncol, 2003, 21: 1675-1681.
  • 8Birner P, Oberhuber G, Stani J, et al. Evaluation of the united states food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer[J]. Clin Cancer Res, 2001, 7(6): 1669-1675.
  • 9Apantaku L M. Breast cancer diagnosis and screening[J]. Am Fam Physician, 2000, 62: 596-602.
  • 10Lipton A, Ali S M, Leitzed K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer[J]. J Clin Oncol, 2002, 20(6): 1467-1472.

共引文献31

同被引文献18

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部